Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.

Hata A, Ninomaru T, Okada H, Kogure Y, Oki M, Katakami N, Kijima T, Yokoyama T, Matsumoto H, Sato Y, Kato T, Sugawara S, Sawada T, Yoshimura K, Seto T, Nakagawa K, Okamoto I, Yamamoto N, West Japan Oncology Group

Open source

DOI: 10.1016/s1470-2045(25)00462-0
Published: 2025 Nov
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00462-0,
  title = {Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50\% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.},
  author = {Hata A and Ninomaru T and Okada H and Kogure Y and Oki M and Katakami N and Kijima T and Yokoyama T and Matsumoto H and Sato Y and Kato T and Sugawara S and Sawada T and Yoshimura K and Seto T and Nakagawa K and Okamoto I and Yamamoto N and West Japan Oncology Group},
  year = {2025},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(25)00462-0},
  url = {https://doi.org/10.1016/s1470-2045(25)00462-0}
}

RIS

TY  - JOUR
TI  - Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.
AU  - Hata A
AU  - Ninomaru T
AU  - Okada H
AU  - Kogure Y
AU  - Oki M
AU  - Katakami N
AU  - Kijima T
AU  - Yokoyama T
AU  - Matsumoto H
AU  - Sato Y
AU  - Kato T
AU  - Sugawara S
AU  - Sawada T
AU  - Yoshimura K
AU  - Seto T
AU  - Nakagawa K
AU  - Okamoto I
AU  - Yamamoto N
AU  - West Japan Oncology Group
PY  - 2025
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(25)00462-0
UR  - https://doi.org/10.1016/s1470-2045(25)00462-0
ER  -

APA

A, H., T, N., H, O., Y, K., M, O., N, K., T, K., T, Y., H, M., Y, S., T, K., S, S., T, S., K, Y., T, S., K, N., I, O., N, Y., & Group, W. J. O. (2025). Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00462-0

Source records

pubmed · retrieved 2026-09-27T15:36:55.160Z